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Malignant gastrointestinal stromal tumours (GIST) have a poor prognosis. Since these tumours are resistant to conventional radiation
and chemotherapy, surgery has been the mainstay of treatment. However, surgery is usually inadequate for the treatment of
malignant GIST. Imatinib, a KIT tyrosine kinase inhibitor, has recently been found to have a dramatic antitumour effect on GIST. In this
centre-based study of 17 consecutive patients with high-risk or overtly malignant GIST, imatinib was used in three different settings –
palliatively, adjuvantly, and neoadjuvantly. The treatment was found to be safe and particularly effective in tumours with activating
mutations of exon 11 of the KIT gene. Clinical response to imatinib treatment correlated morphologically to tumour necrosis,
hyalinisation, and reduced proliferative activity. The value of neoadjuvant imatinib treatment was illustrated in one case.
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Gastrointestinal stromal tumour (GIST), the most common
mesenchymal tumour of the alimentary tract, has a wide clinical
spectrum and highly variable prognosis. The outcome of malignant
GIST is extremely poor (DeMatteo et al, 2000). Since GIST is
resistant to conventional chemotherapy and radiation, complete
surgical resection has been the only available treatment. However,
surgery is often inadequate for advanced GIST.
GIST has been found to differentiate towards a pacemaker cell
phenotype and to express the KIT tyrosine kinase receptor
uniformly (Hirota et al, 1998; Kindblom et al, 1998). In addition,
they frequently exhibit activating mutations of the KIT proto-
oncogene (Hirota et al, 1998; Lasota et al, 1999; Sakurai et al, 1999;
Taniguchi et al, 1999; Rubin et al, 2001; Andersson et al, 2002).
Such activating KIT gene mutations are potential targets for
therapeutic intervention with imatinib, a novel competitive
inhibitor of a family of tyrosine kinase receptors including BCR-
ABL, ABL, KIT, and PDGF-R.
Joensuu et al (2001) have recently reported the first successful
treatment of a patient with metastatic GIST using imatinib.
Preliminary results of several trials indicate that imatinib is an
effective and safe treatment in patients with unresectable and/or
metastatic GIST (Van Oosterom et al, 2001; Demetri et al, 2002).
We report the results of a consecutive series of 17 patients with
high risk and overtly malignant GIST, who were treated at our
centre using imatinib in palliative, adjuvant, and neoadjuvant
settings.
PATIENTS, TUMOURS, AND METHODS
Patients
Patients with ‘high-risk’ (Fletcher et al, 2002) or overtly malignant
GIST (metastatic disease at presentation), who were admitted to
Sahlgrenska University Hospital from May 2001 to September
2002, were included in this study (n¼17, Table 1). Clinical data at
the time of initial diagnosis and at the initiation of imatinib
treatment are detailed in Table 1. Patient 1, who was given imatinib
neoadjuvantly, is described in detail in the next section. Three of
the five patients (cases 2, 3, and 16) who were treated with
adjuvant imatinib had been surgically treated for rectal GIST: two
were primary tumours and the other a local recurrence. None of
these three patients had clinical or radiographic evidence of
residual tumour following surgery; however, microscopic exam-
ination revealed that all had intralesional surgical margins. A
fourth patient (case 15) with a small bowel GIST believed to be
completely surgically removed also had intralesional margins
microscopically. The fifth patient (case 4) who received adjuvant
treatment had a gastric GIST. This patient had undergone five
surgical resections for peritoneal and liver metastases during a 12-
year period prior to receiving adjuvant imatinib. No residual
tumour was detected in this patient following the last surgery. Of
11 patients who received palliative treatment, 10 had an Received 9 July 2002; revised 27 January 2003; accepted 27 January 2003
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lunresectable primary tumour peritoneal metastases and/or liver
metastases at the time of imatinib induction; the remaining patient
had pulmonary metastases. Five of the 11 patients who received
palliative imatinib had two to five surgical resections of tumour
prior to receiving imatinib. The time interval from initial diagnosis
of GIST to induction with imatinib is given in Table 1.
All resected or biopsied primary tumours, recurrences, and
metastases were histologically reviewed. Histologically, three
tumours were predominantly epithelioid, eight predominantly
spindled, and six mixed spindled and epithelioid. The number of
mitotic figures per 50 consecutive high-power fields (h.p.f.¼
0.113mm
2) was recorded as o2, 2–5, 6–10, and 410/50h.p.f.;
proliferative activity was assessed visually estimating the percen-
tage of Ki67-immunopositive tumour cells using MIB1 (see
Table 1). Immunostains for CD117, CD34, a-smooth muscle actin,
desmin, and S100 protein were performed in all 17 cases and found
to be positive in 17, 14, two, zero, and zero cases, respectively.
Treatment with imatinib (400mg p.o. once daily) was given
neoadjuvantly (n¼1), adjuvantly (n¼5), or palliatively (n¼11)
following recommendations given by Van Oosterom et al (2001)
and side effects were monitored in agreement with the US National
Cancer Institute Common Toxicity Criteria (Version 2.0) (Cancer
Therapy Evaluation Program, 1999). Objective tumour response
was evaluated by spiral computed tomography (CT) (5mm
contiguous reconstruction algorithm) 3, 6, and 12 months after
initiating treatment with imatinib and categorised according to the
RECIST (Therasse et al, 2000). Magnetic resonance imaging (MRI)
(contiguous cuts of 10mm or less) was performed in the patient
who received neoadjuvant therapy (case 1). Positron-emission
tomography (PET) with [
18F]fluorodeoxyglucose (
18F-FDG) as
tracer was performed before and during treatment with imatinib in
10 patients (Table 1).
RNA and DNA isolation and nucleotide sequence analyses
RNA and cDNA were prepared from fresh-frozen tissues in nine
cases (cases 1–9) as previously described (Andersson et al, 2002).
Genomic DNA was prepared from three 5-mm-thick sections of
paraffin-embedded tumour material in eight cases (cases 10–17)
using the DEXPAT kit (TAKARA, Kyoto, Japan). Exon 11 of the
KIT gene was amplified by PCR and directly sequenced in all cases
as well as cloned and sequenced in 10 cases (cases 2, 3, 7, 9–11,
13–15, 17) as previously described (Andersson et al, 2002) using
primers PCRKIT21s and PCRKIT22as for cDNA and primers
PCRKIT31s and 34as for genomic DNA. Primer sequences are
shown in Table 2.
RESULTS
Imatinib treatment
The results of imatinib treatment results are summarised in
Table 1. Results regarding case 1 are described in detail below.
None of the five patients who received adjuvant treatment have
had recurrent disease during 7–13 months of follow-up. Eight of
Table 1 Clinical data and tumour characteristics at the time of initial diagnosis and imatinib induction, and response to imatinib in 17 patients with
malignant GIST
Status at initial diagnosis Status at imatinib induction Imatinib treatment
Case Age/sex
11 tumour
site and
size (cm)
Ki67%/
MR
Exon 11
KIT
mutation
Mets at
initial
diag.
Number
previous
surgeries
Interval: 11
tumour
diag
to imatinib
(months)
Disease
status
Clinical
setting
FU
(months)
Response
CT eval.
Response
PET eval.
Side
effects
1 56/M SB/20 10%/2–5 W557R L None 3 PT, P, L Neoadjuvant 10 PR No residual
uptake
None
2 48/M R/9 10%/2–5 K558_V560del None 1 1.5 NED
a Adjuvant 13 NED No uptake None
3 55/M R/4.5 5%/o2 W557M None 2 180 NED
b Adjuvant 12 NED Not done None
4 10/F S/3.5 5%
c/2–5 None None 5 144 NED
d Adjuvant 9.5 NED No uptake Oedema
grade 2
5 74/M D/11 15%/6–10 None None 2 22 P, L Palliative 13 PD Additional
uptake
Oedema
grade 1
6 70/M D/25 25%/6–10 None L 1 1 PT, L Palliative 9 PD Not done None
7 47/M SB/29 30%/410 W557_E561del P 1 7 PT, P, L Palliative 14.5 PR No residual
uptake
None
8 63/M SB/15 50%/2–5 None P, L 2 3 P, L Palliative 9 PR Decreased
uptake
None
9 70/M SB/16 20%/410 V559_E561del P, L 3 14 P, L Palliative 18 PR Not done None
10 72/M SB/12 10%/410 N564_L576del P, L 1 3 P, L Palliative 9.5 PR Not done None
11 53/M SB/6 10%/410 P551del,M552L L 1 4 L Palliative 14.5 PR Not done Oedema
grade 2
12 62/M SB/5 10%/410 None None 1 16 Pu Palliative 9 SD Not done None
13 56/M D/6 5%/6–10 K558_V559del,
V560I
None 5 84 P, L Palliative 12.5 PR Not done Oedema
grade 1
14 68/F SB/10 10%/6–10 V559del None 2 12 L Palliative 6 PR No residual
uptake
None
15 36/M SB/10 5%/2–5 W557_K558del P 1 4 NED Adjuvant 7 NED No uptake None
16 62/M R/15 15%/6–10 P551_E554del None 1 2 NED
a Adjuvant 7 NED No uptake None
17 74/M R/30 25%/410 K558S,V559del P 1 9 P Palliative 8 PR No residual
uptake
None
D¼duodenum; del¼deletion; diag.¼diagnosis; eval.¼evaluation; F¼female; FU¼follow-up; L¼liver mets; M¼male; mets¼metastases; MR¼mitotic rate (mitoses/
50h.p.f.); NED¼no evidence of disease; P¼peritoneal mets; PD¼progressive disease (420% increase in the greatest diameter of the target lesion or appearance of one or
more new lesions); PR¼partial response (430% decrease in the greatest diameter of target lesion); PT¼primary tumour; Pu¼pulmonary mets; R¼rectum; S¼stomach;
SB¼small bowel; SD¼stable disease; 11¼primary;
aResection of primary rectal GIST with intralesional margins.
bResection of local recurrence with intralesional margins.
cFocally 25% of cells positive for Ki67.
dAfter five surgical procedures for peritoneal mets and liver mets.
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partial response (defined as 430% decrease in the largest
dimension of the target lesion on CT) over a follow-up period of
6–18 months. One of the 11 patients has had stable disease. Two
patients in whom no KIT mutations were detected (cases 5 and 8)
died of myocardial infarcts 9 and 13 months, respectively, after
imatinib induction. Both patients had progressive tumour disease
at the time of death.
None of the 17 patients in this study have developed serious side
effects. Notably, there was neither intra-abdominal nor gastro-
intestinal haemorrhage in any patient. Four patients developed
transient oedema, grade 1–2.
Case report (patient 1), neoadjuvant imatinib treatment
A 56-year-old man was admitted with a palpable, huge tumour
filling the lower abdomen. Computed tomography and MRI
examinations revealed a 35cm tumour, occupying most of the
pelvis and lower abdominal cavity in addition to mesenteric
metastases and six liver metastases involving both lobes of the
liver. Core needle biopsies of the intra-abdominal tumour and the
liver metastases were diagnosed as a malignant spindled and
epithelioid GIST. Mutation analysis of core needle samples
revealed a substitution of tryptophan to arginine in amino-acid
position 557 (W557R) of exon 11 of the KIT gene. Positron-
Table 2 Primer sequences
Primer name Primer sequence
PCRKIT21s 50-ACTCCTTTGCTGATTGGTTTCGT-30
PCRKIT22as 50-AATGGTGCAGGCTCCAAGTAGAT-30
PCRKIT31s 50-CCAGAGTGCTCTAATGACTG-30
PCRKIT34as 50-CTGTTATGTGTACCCAAAAAGG-30
Sp6s 50-ATTTAGGTGACACTATAG-30
T7as 50-TAATACGACTCACTATAGGG-30
s¼sense; as¼antisense.
Figure 1 Case 1, neoadjuvant imatinib treatment. Positron-emission tomography examinations before (A), after 3 weeks (B), and after 12 weeks (C)o f
imatinib treatment. The increased uptake of the tracer [
18F] fluorodeoxyglucose that was seen in a huge abdominal tumour before treatment cannot be
detected at PET examinations after 3 and 12 weeks of imatinib treatment. Corresponding CT examinations before (D), after 3 weeks (E), and after 12
weeks of imatinib treatment (F). During 12 weeks of treatment, the tumour decreased from 35 to 18cm. Corresponding sagittal gadolinium-enhanced T2-
weighted and T1-weighted MRI before (G) and after 12 weeks (I) of treatment, respectively, showing tumour reduction. After 3 months of treatment, the
tumour could be completely excised, leaving the rectum intact (H).
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lemission tomography scan showed increased uptake in the intra-
abdominal tumour and all liver metastases. Both the primary
tumour and the liver metastases were considered unresectable.
Imatinib treatment was therefore initiated. Positron-emission
tomography scan was repeated after 3 and 12 weeks; no tracer
uptake was seen at either examination. After 3 weeks of imatinib
treatment, a marked decrease in tumour size was seen on CT
examination. After 12 weeks, the tumour had decreased from 35 to
18cm in greatest dimension, and all six liver metastases had
become entirely cystic. Since the primary tumour was now
considered to be resectable, complete surgical excision of the
tumour (found to originate from the ileum) and multiple
mesenteric metastases were performed leaving the rectum,
bladder, and prostate intact (Figure 1A–I). The patient is still on
the same dose of imatinib without side effects 7 months after
surgery. Positron-emission tomography scan shows no residual
uptake and CT demonstrates a stable partial response (lesions with
low attenuation).
Morphologic response to imatinib treatment
Tumour tissue from three patients (cases 1, 5, and 8) was studied
during imatinib treatment. The tumour of the patient, who
received 3 months of neoadjuvant imatinib treatment (case 1)
showed extensive areas of tumour necrosis, hyalinised areas with
sparse, scattered tumour cells containing small, condensed nuclei
and areas of viable tumour histologically similar to those seen in
pretreatment biopsies. Prior to imatinib treatment, the tumour
revealed a mitotic rate of 5/50 h.p.f. and a 10% proliferative index
compared to a post-treatment mitotic rate of 0/50 h.p.f. and a
proliferative index far less than 1%. (Figure 2A–G). In case 5, the
mitotic rate decreased from 8 to 5/50 h.p.f. and the proliferative
index from 15 to 5% after 10 months of treatment, whereas no
change in either parameter was seen in case 8 after 7 months of
treatment.
KIT mutation analysis
Typical gain-of-function exon 11 KIT mutations were found in 12
of 17 patients, including two point mutations (cases 1 and 3), three
point mutations and deletions (cases 11, 13, and 17), and seven
deletions (cases 2, 7, 9, 10, 14, 15, and 16) (see Table 1). Eight of
nine patients with a partial response had an exon 11 mutation. One
patient with a partial response (case 6), two patients with
progressive disease (cases 5 and 6), and one patient with stable
disease (case 12) had no exon 11 KIT mutations. Four of the five
patients who received adjuvant treatment had an exon 11
mutation.
DISCUSSION
This report indicates the utility of neoadjuvant imatinib treatment
in downstaging selected patients with malignant GIST, thereby
rendering the primary tumours and metastases resectable in some
cases. As illustrated in case 1, preoperative imatinib treatment
during a 12-week period led to dramatic reduction of tumour size,
allowing complete removal of the tumour.
Eight of nine patients with a partial response to imatinib,
including the patient treated neoadjuvantly, had activating exon 11
KIT mutations. In contrast, none of the three patients with
progressive or stable disease had exon 11 mutations. These results
agree with a recent report demonstrating a significantly higher
response rate to imatinib among patients with GIST containing
exon 11 KIT mutations compared to those without such mutations
(Heinrich et al, 2002a,b). Interestingly, one patient in our series
(case 8) whose tumour lacked an exon 11 KIT mutation had a
partial response to imatinib by CT and a significantly reduced
tracer uptake on PET. The tumour of another patient with
progressive disease (case 5) also lacked an exon 11 mutation and
showed a significant reduction in proliferative activity after 10
weeks of imatinib treatment. These observations as well as those of
Heinrich et al (2002a,b) suggest that activating KIT mutations may
not necessarily be a prerequisite for imatinib treatment.
The morphologic findings of extensive sclerosis and hyalinisa-
tion with scattered, shrunken tumour cells replacing previously
viable tumour after 3 months of neoadjuvant imatinib (case 1) are
in agreement with those reported by Joensuu et al (2001). In this
case and another (case 5), we also observed foci of highly cellular,
viable tumour after imatinib treatment, similar to those seen in
pretreatment biopsies but with dramatically reduced proliferative
activity. These findings may indicate tumour heterogeneity. They
also correspond with reports that imatinib occupies the ATP-
binding site of the target kinase receptor and prevents subsequent
autophosphorylation, thereby leading to the onset of apoptosis and
Figure 2 Case 1, neoadjuvant imatinib treatment. Pretreatment core needle biopsies of a huge abdominal tumour and liver metastases showing
characteristic features of a malignant spindled and epithelioid GIST (A) that is immunoreactive for CD117 (B) and MIB1 (Ki67 proliferative index¼10%)
(C). After 3 months of imatinib treatment, the tumour shows extensive hyalinisation with scattered residual tumour cells (D), necrosis (E), cyst formation
and areas of viable tumour (F) in which the proliferative index is virtually zero (only a few inflammatory cells next to a vessel are MIB1 immunoreactive, G).
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ldecreased proliferation (Goldman and Melo, 2001; Tuveson et al,
2001).
The recent development of imatinib has drastically improved the
limited therapeutic options and the dismal outlook for patients
with advanced, malignant GIST. Additional studies are needed to
establish the long-term effectiveness of imatinib treatment and to
further define treatment strategies combining imatinib and
surgery. We believe that surgery will continue to play a crucial
role in the treatment of malignant GIST.
In conclusion, this study illustrates several new and interesting
aspects regarding imatinib treatment in malignant GIST, including
a role for neoadjuvant treatment that may allow surgical resection
of large primary tumours and metastases; a high response rate to
imatinib in patients whose tumours have exon 11 KIT mutations; a
potential role for imatinib even in patients without exon 11
mutations; and histologic documentation of different tumour
responses to imatinib corresponding clinically to reduction in
tumour volume. Our results also indicate a role for adjuvant
treatment with imatinib, which is currently being investigated in
prospective randomised clinical trials.
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